戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 f the human CCKB/gastrin receptor coupled to diphtheria toxoid.
2  those who had received at least one dose of diphtheria toxoid.
3 ached to protein carriers such as tetanus or diphtheria toxoids.
4 eness of one, two, or three or more doses of diphtheria toxoid against diphtheria among 40- to 49-yea
5 ination coverage with three or more doses of diphtheria toxoid among adults and children.
6 mmunogenicity and safety of a single dose of diphtheria toxoid among adults, blood samples for detect
7 the complete primary vaccination series with diphtheria toxoid and adults 40-49 years of age were the
8                       Noninferiority of anti-diphtheria toxoid and anti-tetanus toxoid immune respons
9  reduced the interval since the last dose of diphtheria toxoid and improved protection against diphth
10  in the infants and their immune response to diphtheria toxoid and pneumococcal vaccination.
11 nd did not affect infant immune responses to diphtheria toxoid and pneumococcal vaccination.
12 Control and Prevention recommend tetanus and diphtheria toxoids and acellular pertussis (Tdap) vaccin
13 ids and acellular pertussis, and tetanus and diphtheria toxoids and acellular pertussis vaccines are
14 us, meningococcal conjugate, and tetanus and diphtheria toxoids and acellular pertussis vaccines.
15  response, a dose of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccin
16 al immunization with tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccin
17 n of infants through tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccin
18 1, the US introduced tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccin
19 recommended that the tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine (Tdap
20 accine (RSVpreF) and tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine adsor
21 single dose of Tdap (tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine).
22 nt women receive the tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine.
23 aving received Tdap (tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine; 31.6
24       In 2012, Tdap (tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis) vaccine was
25  (eg, meningococcal; tetanus toxoid, reduced diphtheria toxoid, and reduced acellular pertussis; and
26                   In contrast, the mean anti-diphtheria toxoid antibody response increased with incre
27 nt meningococcal conjugate vaccine that uses diphtheria toxoid as the protein carrier (MCV4-DT).
28 ted a panel of diverse hMAbs that recognized diphtheria toxoid, as well as a variety of recombinant p
29 d W-135) meningococcal vaccine conjugated to diphtheria toxoid at 1 of 3 doses and were monitored for
30 alled in January 1999 because of a subpotent diphtheria toxoid component.
31 ter vaccination with either PRP alone or the diphtheria toxoid conjugate of PRP.
32 he A, C, Y, and W-135 Neisseria meningitidis-diphtheria toxoid conjugate vaccine, when given to healt
33  a C. neoformans serotype D strain 24067 GXM-diphtheria toxoid conjugate.
34 this and other studies, low effectiveness of diphtheria toxoid-containing vaccine was suspected to be
35 e produce a single antigenic type of DT, and diphtheria toxoid continues to be an effective vaccine f
36 ere then conjugated with the carrier protein diphtheria toxoid cross-reactive material (CRM) 197 (DT)
37 otein, including keyhole limpet hemocyanion, diphtheria toxoid cross-reactive material (CRM) 197 (DT)
38 P13 was conjugated to tetanus toxoid (TT) or diphtheria toxoid (DT) and administered subcutaneously i
39 tion) were conjugated to the carrier protein diphtheria toxoid (DT) and used to immunize animals.
40 ), pertactin (Prn), tetanus toxoid (TT), and diphtheria toxoid (DT) were measured using commercially
41 w DC pulsed in vitro with an intact protein (diphtheria toxoid (DT)) produce exosomes that induce, in
42 onjugated to an immunogenic carrier protein, diphtheria toxoid (DT), and formulated in a nanoparticul
43  conjugated to the T cell-dependent protein (diphtheria toxoid [DT] [CRM197]).
44 uvants that have activity on the skin, using diphtheria toxoid (DTx) and tetanus toxoid as model anti
45 han microparticles with two antigens (TT and diphtheria toxoid) entrapped simultaneously.
46  infection, required at least three doses of diphtheria toxoid for reliable protection against diseas
47 ning only 12 aa from GAS, when conjugated to diphtheria toxoid, has been shown to protect mice agains
48 dred fifty samples were studied by ELISA for diphtheria toxoid IgG antibodies to assess the utility o
49    This study suggests that one dose of 2 Lf diphtheria toxoid is highly effective in raising DAT to
50                    However, S2 conjugated to diphtheria toxoid is highly immunogenic and induces Abs
51  30 days after immunization with Td (tetanus-diphtheria toxoids; manufactured by Serum Institute of I
52 ]) and to have a time since the last dose of diphtheria toxoid of 3-4 years (3.1 [1.1-9.1]) or 5-7 ye
53 ng Ag derived from allografts, we used CD11c-diphtheria toxoid receptor mice to conditionally ablate
54 egies, the immunogenicity of the tetanus and diphtheria toxoids (Td) vaccine was assessed.
55 agglutinin (FHA) coadministered with tetanus-diphtheria toxoids (Td), compared to a licensed tetanus-
56 idered eligible for vaccination with tetanus-diphtheria toxoids (Td).
57 s documented; (6) neonatal immunization with diphtheria toxoid, tetanus toxoid, and acellular pertuss
58 ria toxoid-tetanus toxoid-pertussis (DTP) or diphtheria toxoid-tetanus toxoid (DT) vaccine, 1 to 3 do
59  Previous studies suggested that tetanus and diphtheria toxoids (TTD and DTD, respectively) contain "
60 f maintaining high levels of age-appropriate diphtheria toxoid vaccination, surveillance, accessible
61 r dose of V-TT CV (n=22) or licensed tetanus-diphtheria toxoid vaccine (Td) (n=10; double-masked desi
62                               Three doses of diphtheria toxoid vaccine are 87% (95% CI, 68-97%) effec
63 mized to receive III-TT conjugate or tetanus diphtheria toxoid vaccine in a multicenter, observer-bli
64                        Receipt of 3 doses of diphtheria toxoid vaccine is 87% (95% CrI, 68%-97%) effe
65 ings, which showed that protection by the J8-diphtheria toxoid vaccine is Ab-mediated and suggest tha
66 sive adult coverage rates for first doses of diphtheria toxoid vaccine, communication interventions e
67  (92%) had received three or more doses of a diphtheria toxoid vaccine, compared with 72% of case-pat
68 trol strategies, immunogenicity of a tetanus-diphtheria toxoids vaccine (Td) containing 2 limits of f
69                            A booster dose of diphtheria-toxoid vaccine given to children in the Russi
70 ontrols had received at least three doses of diphtheria-toxoid vaccine.
71 nus toxoid was 1.22 (0.91-1.62), p=0.18, and diphtheria toxoid was 0.97 (0.83-1.13), p=0.72.
72 Td) containing 2 limits of flocculation (Lf) diphtheria toxoid was evaluated.
73  diphtheria toxin reacted with formaldehyde (diphtheria toxoid) was compared to that of diphtheria to
74  coadministered antigens such as tetanus and diphtheria toxoids when applied to the skin.
75 47%) controls had received a booster dose of diphtheria toxoid within the previous 2 years.